NO303498B1 - AnalogifremgangsmÕte for fremstilling av terapeutisk aktive forbindelser - Google Patents
AnalogifremgangsmÕte for fremstilling av terapeutisk aktive forbindelser Download PDFInfo
- Publication number
- NO303498B1 NO303498B1 NO910958A NO910958A NO303498B1 NO 303498 B1 NO303498 B1 NO 303498B1 NO 910958 A NO910958 A NO 910958A NO 910958 A NO910958 A NO 910958A NO 303498 B1 NO303498 B1 NO 303498B1
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- compound
- indole
- tetrahydro
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 7
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 20
- -1 imino-1H-indole-5,2-di-carbonyl Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 229940125904 compound 1 Drugs 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 150000002475 indoles Chemical class 0.000 claims description 6
- 229940125782 compound 2 Drugs 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 4
- 239000012445 acidic reagent Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000010171 animal model Methods 0.000 abstract description 2
- 239000006096 absorbing agent Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- ATFRLAFCRGJKAA-UHFFFAOYSA-N 5-[(2-carboxy-1h-indol-5-yl)carbamoylamino]-1h-indole-2-carboxylic acid Chemical compound C1=C2NC(C(O)=O)=CC2=CC(NC(=O)NC=2C=C3C=C(NC3=CC=2)C(=O)O)=C1 ATFRLAFCRGJKAA-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UOWVMDUEMSNCAV-UHFFFAOYSA-N antibiotic cc 1065 Chemical compound N1C=2C(OC)=C(O)C=3N(C(N)=O)CCC=3C=2C=C1C(=O)N1CCC(C=2C=3)=C1C(O)=C(OC)C=2NC=3C(=O)N1CC2CC22C1=CC(=O)C1=C2C(C)=CN1 UOWVMDUEMSNCAV-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- USSLMJFJRWUITI-UHFFFAOYSA-N ethyl 5-[(2-ethoxycarbonyl-1h-indol-5-yl)carbamoylamino]-1h-indole-2-carboxylate Chemical compound C1=C2NC(C(=O)OCC)=CC2=CC(NC(=O)NC=2C=C3C=C(NC3=CC=2)C(=O)OCC)=C1 USSLMJFJRWUITI-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- PUPKPAZSFZOLOR-UHFFFAOYSA-N n,n-dimethylformamide;toluene Chemical compound CN(C)C=O.CC1=CC=CC=C1 PUPKPAZSFZOLOR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000005869 (methoxyethoxy)methanyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- MOQCFMZWVKQBAP-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)benzoyl]-n-(4-chlorophenyl)piperidine-3-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(CCC2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 MOQCFMZWVKQBAP-UHFFFAOYSA-N 0.000 description 1
- ULUNQYODBKLBOE-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)-1h-pyrrole Chemical compound C1=CNC(C=2NC=CC=2)=C1 ULUNQYODBKLBOE-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DSRXQXXHDIAVJT-UHFFFAOYSA-N acetonitrile;n,n-dimethylformamide Chemical compound CC#N.CN(C)C=O DSRXQXXHDIAVJT-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WCGCOZXVVVIAEF-UHFFFAOYSA-N ethyl 5-amino-1h-indole-2-carboxylate Chemical compound NC1=CC=C2NC(C(=O)OCC)=CC2=C1 WCGCOZXVVVIAEF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Error Detection And Correction (AREA)
- Semiconductor Integrated Circuits (AREA)
- Amplifiers (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Solid State Image Pick-Up Elements (AREA)
- Artificial Filaments (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Television Systems (AREA)
- Television Receiver Circuits (AREA)
- Stereophonic System (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24335088A | 1988-09-12 | 1988-09-12 | |
| PCT/US1989/003329 WO1990002746A1 (en) | 1988-09-12 | 1989-08-07 | Novel cc-1065 analogs having two cpi subunits |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO910958D0 NO910958D0 (no) | 1991-03-11 |
| NO910958L NO910958L (no) | 1991-05-10 |
| NO303498B1 true NO303498B1 (no) | 1998-07-20 |
Family
ID=22918400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO910958A NO303498B1 (no) | 1988-09-12 | 1991-03-11 | AnalogifremgangsmÕte for fremstilling av terapeutisk aktive forbindelser |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5541339A (cs) |
| JP (1) | JP3380237B2 (cs) |
| KR (1) | KR0137959B1 (cs) |
| AT (1) | ATE198335T1 (cs) |
| AU (1) | AU632288B2 (cs) |
| CA (1) | CA1340215C (cs) |
| DE (1) | DE68929275T2 (cs) |
| DK (1) | DK175458B1 (cs) |
| FI (1) | FI103668B1 (cs) |
| GR (1) | GR3035589T3 (cs) |
| LV (1) | LV12806B (cs) |
| NO (1) | NO303498B1 (cs) |
| TW (1) | TW217383B (cs) |
| WO (1) | WO1990002746A1 (cs) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2149768T3 (es) * | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US5502068A (en) * | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
| JP4414142B2 (ja) | 2001-05-11 | 2010-02-10 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 特異的結合タンパク質およびその使用 |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| CN1612733A (zh) | 2001-11-09 | 2005-05-04 | 贝林格尔·英格海姆药物公司 | 用作蛋白激酶抑制剂的苯并咪唑类 |
| US7138420B2 (en) * | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
| CA2501547A1 (en) * | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| US20070213374A1 (en) * | 2003-07-07 | 2007-09-13 | Merck Patent Gmbh | Malonamide Derivatives |
| WO2005079791A1 (en) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| JP2009504756A (ja) * | 2005-08-17 | 2009-02-05 | シェーリング コーポレイション | 新規な高親和性のチオフェンベースおよびフランベースのキナーゼリガンド |
| CA2676244C (en) | 2007-01-25 | 2017-01-17 | Kwok-Kin Wong | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| AU2008227123B2 (en) | 2007-03-15 | 2014-03-27 | Ludwig Institute For Cancer Research Ltd. | Treatment method using EGFR antibodies and src inhibitors and related formulations |
| US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| EP2188311B1 (en) | 2007-08-14 | 2016-10-05 | Ludwig Institute for Cancer Research Ltd. | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| HUE035798T2 (en) | 2008-11-03 | 2018-05-28 | Syntarga Bv | CC-1065 analogues and conjugates |
| EP3056203B1 (en) | 2010-04-21 | 2017-12-13 | Syntarga B.V. | Conjugates of cc-1065 analogs and bifunctional linkers |
| EP3388060A1 (en) | 2012-10-22 | 2018-10-17 | Arnold Glazier | Methods for the effective treatment of metastatic cancer |
| DE102013012622A1 (de) * | 2013-07-30 | 2015-02-05 | Clariant lnternational Ltd | Neue sterisch gehinderte cyclische Amine |
| LT3092010T (lt) | 2014-01-10 | 2018-10-25 | Synthon Biopharmaceuticals B.V. | Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų |
| DK3099692T5 (da) * | 2014-01-27 | 2020-03-16 | Pfizer | Bifunktionelle cytotoksiske midler |
| CA2954934C (en) | 2014-06-30 | 2023-09-26 | Glykos Finland Oy | Drug derivative and conjugates |
| DE102015000124A1 (de) * | 2015-01-07 | 2016-07-07 | Clariant International Ltd. | Verfahren zur Stabilisierung von Polyamiden |
| JP6782250B2 (ja) * | 2015-03-20 | 2020-11-11 | ファイザー・インク | Ｃｔｉファーマコフォアを含有する二官能性細胞毒性剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4169888A (en) * | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
| US4301248A (en) * | 1979-12-21 | 1981-11-17 | Bristol-Myers Company | Fermentation process for making rachelmycin |
| US4413132A (en) * | 1980-11-18 | 1983-11-01 | The Upjohn Company | Antibiotic CC-1065 indoline intermediates |
| US4912227A (en) * | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| CA1238907A (en) * | 1984-02-21 | 1988-07-05 | Robert C. Kelly | 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds |
| GB8528848D0 (en) * | 1985-11-22 | 1985-12-24 | Davy Mckee Poole | Rolling mills |
| AU617304B2 (en) * | 1986-12-19 | 1991-11-28 | Pharmacia & Upjohn Company | Novel cc-1065 analogs |
-
1989
- 1989-08-07 US US07/659,415 patent/US5541339A/en not_active Expired - Fee Related
- 1989-08-07 JP JP50923689A patent/JP3380237B2/ja not_active Expired - Fee Related
- 1989-08-07 KR KR1019900700977A patent/KR0137959B1/ko not_active Expired - Fee Related
- 1989-08-07 WO PCT/US1989/003329 patent/WO1990002746A1/en active IP Right Grant
- 1989-08-07 AU AU41922/89A patent/AU632288B2/en not_active Ceased
- 1989-08-21 CA CA000608908A patent/CA1340215C/en not_active Expired - Fee Related
- 1989-08-23 TW TW078106510A patent/TW217383B/zh active
- 1989-09-04 AT AT89308920T patent/ATE198335T1/de not_active IP Right Cessation
- 1989-09-04 DE DE68929275T patent/DE68929275T2/de not_active Expired - Fee Related
-
1991
- 1991-03-08 DK DK41791A patent/DK175458B1/da not_active IP Right Cessation
- 1991-03-11 NO NO910958A patent/NO303498B1/no unknown
- 1991-03-11 FI FI911193A patent/FI103668B1/fi not_active IP Right Cessation
-
2001
- 2001-03-15 GR GR20010400433T patent/GR3035589T3/el not_active IP Right Cessation
- 2001-12-27 LV LV010180A patent/LV12806B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3380237B2 (ja) | 2003-02-24 |
| DK175458B1 (da) | 2004-11-01 |
| NO910958D0 (no) | 1991-03-11 |
| ATE198335T1 (de) | 2001-01-15 |
| DK41791D0 (da) | 1991-03-08 |
| GR3035589T3 (en) | 2001-06-29 |
| KR900701801A (ko) | 1990-12-04 |
| US5541339A (en) | 1996-07-30 |
| TW217383B (cs) | 1993-12-11 |
| FI911193A0 (fi) | 1991-03-11 |
| LV12806A (en) | 2002-03-20 |
| LV12806B (lv) | 2002-05-20 |
| CA1340215C (en) | 1998-12-15 |
| WO1990002746A1 (en) | 1990-03-22 |
| AU632288B2 (en) | 1992-12-24 |
| DE68929275D1 (de) | 2001-02-01 |
| JPH04500664A (ja) | 1992-02-06 |
| DE68929275T2 (de) | 2001-05-23 |
| AU4192289A (en) | 1990-04-02 |
| NO910958L (no) | 1991-05-10 |
| KR0137959B1 (ko) | 1998-05-15 |
| FI103668B (fi) | 1999-08-13 |
| FI103668B1 (fi) | 1999-08-13 |
| DK41791A (da) | 1991-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO303498B1 (no) | AnalogifremgangsmÕte for fremstilling av terapeutisk aktive forbindelser | |
| AU776475B2 (en) | Isomeric fused pyrrolocarbazoles and isoindolones | |
| EP1193270B1 (en) | Pyrrolobenzodiazepines | |
| CA2420592C (en) | Fused pyrrolocarbazoles against inflammation | |
| EP0109047B1 (en) | Total synthesis of antitumor antibiotics | |
| KR101412157B1 (ko) | 항종양 활성을 갖는 캄프토테신 유도체 | |
| JP2021502413A (ja) | Ｔｒｋキナーゼ阻害剤としての大環状化合物およびその使用 | |
| KR20150003156A (ko) | 라파마이신 유사체 및 이의 제조 방법 | |
| US5340817A (en) | Method of treating tumors with anti-tumor effective camptothecin compounds | |
| CA3241069A1 (en) | Macrocyclic btk inhibitors | |
| EP2836493B1 (en) | Functionalized thieno-indole derivatives for the treatment of cancer | |
| CN112110977A (zh) | 一类雷公藤红素衍生物、其制备方法及用途 | |
| IE921148A1 (en) | Anti-tumor and anti-psoriatic agents | |
| EP0359454B1 (en) | CC-1065 analogs having two CPI subunits | |
| Wada et al. | The synthetic and biological studies of discorhabdins and related compounds | |
| JP5313895B2 (ja) | 抗腫瘍活性を有するカンプトテシン誘導体 | |
| JPH03173890A (ja) | ピロロ［２，３―ｄ］ピリミジン誘導体，その製造法，用途及び中間体 | |
| SE504862C2 (sv) | Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler | |
| CN114437114A (zh) | 二酮哌嗪类天然产物及衍生物的应用、制备与所得衍生物 | |
| EP0284380B1 (en) | Mitomycin derivatives | |
| US4853385A (en) | 7-N,8-N-Ethylenemitomycin 8-imines | |
| HK127993A (en) | Mitomycin analogs, a process for preparing them and pharmaceutical compositions | |
| CN118373824A (zh) | 取代喹唑啉-4-酮类化合物及其制备方法和用途 | |
| EP4378943A1 (en) | 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof | |
| EP0476443B1 (en) | Mitomycin derivatives |